Loading...
XWAR
BMX
Market cap15mUSD
Jul 22, Last price  
13.50PLN
1D
-2.17%
1Q
6.72%
Jan 2017
178.93%
IPO
70.89%
Name

BioMaxima SA

Chart & Performance

D1W1MN
No data to show
P/E
96.60
P/S
1.21
EPS
0.14
Div Yield, %
—
Shrs. gr., 5y
2.97%
Rev. gr., 5y
8.71%
Revenues
47m
-67.48%
6,669,4287,163,84610,491,70518,818,62020,965,51020,440,95521,965,26026,984,19831,574,52630,817,69230,487,87061,609,50879,088,000143,867,00046,786,000
Net income
586k
-97.97%
610,366539,042998,9531,375,0641,320,371454,8331,454,7471,227,716805,683013,9987,949,00010,243,00028,885,000586,000
CFO
2m
-95.70%
418,323102,8851,832,45101,249,426561,0162,286,8831,439,1421,839,4002,120,2564,927,7823,972,697-132,00037,065,0001,592,000
Dividend
Jun 16, 20230.5 PLN/sh

Profile

BioMaxima S.A. manufactures and distributes reagents for in vitro diagnostics in Poland. Its primary products include diagnostic reagents and analyzers for clinical chemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; and additives and supplements for media. It supplies its products to approximately 2,000 laboratories in Poland, as well as exports in the international markets. BioMaxima S.A. was founded in 2002 and is based in Lublin, Poland.
URL
https://biomaxima.com/
IPO date
Jun 08, 2010
Employees
122
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
46,786
-67.48%
143,867
81.91%
Cost of revenue
45,818
89,637
Unusual Expense (Income)
NOPBT
968
54,230
NOPBT Margin
2.07%
37.69%
Operating Taxes
(399)
6,984
Tax Rate
12.88%
NOPAT
1,367
47,246
Net income
586
-97.97%
28,885
182.00%
Dividends
(2,097)
(1,948)
Dividend yield
2.96%
1.70%
Proceeds from repurchase of equity
45
(4,991)
BB yield
-0.06%
4.36%
Debt
Debt current
3,797
1,718
Long-term debt
9,767
4,772
Deferred revenue
6,871
6,019
Other long-term liabilities
102
94
Net debt
12,061
(6,430)
Cash flow
Cash from operating activities
1,592
37,065
CAPEX
(18,079)
(9,879)
Cash from investing activities
(17,248)
(7,831)
Cash from financing activities
4,252
(19,323)
FCF
(12,094)
44,623
Balance
Cash
1,503
12,920
Long term investments
Excess cash
5,727
Stockholders' equity
37,038
46,769
Invested Capital
66,808
58,670
ROIC
2.18%
85.39%
ROCE
1.44%
83.22%
EV
Common stock shares outstanding
4,318
4,459
Price
16.42
-36.11%
25.70
-2.28%
Market cap
70,900
-38.13%
114,591
-2.79%
EV
82,961
108,161
EBITDA
3,456
56,250
EV/EBITDA
24.00
1.92
Interest
609
475
Interest/NOPBT
62.91%
0.88%